134 related articles for article (PubMed ID: 37878093)
1. Photo elicitation, an approach to better understanding the patient experience with OAAs: pilot study and future implications.
Manojlovich M; Blok A; Wright N; Azhari E; Farris KB; Friese CR; Mackler E; Titler M; Byrnes M
Support Care Cancer; 2023 Oct; 31(12):652. PubMed ID: 37878093
[TBL] [Abstract][Full Text] [Related]
2. Video reflexive ethnography as an intervention to improve oral anti-cancer agent patient education: A pilot study.
Manojlovich M; Rizvi-Toner A; DasGupta R; Farris K; Friese C; Kostoff D; Mackler E; Millisor V; Titler MG
PEC Innov; 2023 Dec; 2():100148. PubMed ID: 37214518
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).
Farris KB; Cadwallader T; Farley J; Gatwood K; Mackler E; Gatwood J
Explor Res Clin Soc Pharm; 2022 Sep; 7():100163. PubMed ID: 35957656
[TBL] [Abstract][Full Text] [Related]
4. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
5. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
6. A Concept Analysis of Oral Anticancer Agent Self-management.
Mason M; Harris MR; Greer JA; Jiang Y
Cancer Nurs; 2022 Mar-Apr 01; 45(2):E374-E387. PubMed ID: 33654013
[TBL] [Abstract][Full Text] [Related]
7. Symptomatogenic zone and network of oroalimentary automatisms in mesial temporal lobe epilepsy.
Wang Y; Wang X; Mo JJ; Sang L; Zhao BT; Zhang C; Hu WH; Zhang JG; Shao XQ; Zhang K
Epilepsia; 2019 Jun; 60(6):1150-1159. PubMed ID: 31095733
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
9. Caregivers' contribution to self-care for patients treated with oral anticancer agents: A qualitative descriptive study.
Sollazzo F; Di Nitto M; Rosito L; Torino F; Alvaro R; Lacarbonara F; Vellone E; Durante A
Eur J Oncol Nurs; 2023 Jun; 64():102327. PubMed ID: 37156057
[TBL] [Abstract][Full Text] [Related]
10. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
11. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
12. Patient symptoms, self-management, and unscheduled healthcare use during the first 6 months of targeted oral anticancer agent therapy: protocol for a mixed-methods US study.
Rizvi-Toner A; Coe AB; Friese CR; Manojlovich M; Wallner L; Farris KB
BMJ Open; 2024 Feb; 14(2):e081375. PubMed ID: 38355181
[TBL] [Abstract][Full Text] [Related]
13. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
14. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Del Monte-Millán M; Hoyo-Muñoz A; Gómez Martínez-Sagrera P; Revuelta-Herrero JL; Marzal-Alfaro B; Gonzalez-Haba E; López-Tarruella Cobo S; Jerez Gilarranz Y; Herranz A; Sanjurjo M; Martin M
Support Care Cancer; 2021 Aug; 29(8):4673-4681. PubMed ID: 33506273
[TBL] [Abstract][Full Text] [Related]
15. Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents.
Dayer L; Dunn E; Pace A; Flowers S
J Am Pharm Assoc (2003); 2016; 56(2):141-4.e2. PubMed ID: 27000164
[TBL] [Abstract][Full Text] [Related]
16. Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Gonzalez-Anleo C; Martin-Conde M; Romero-Jimenez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
JMIR Mhealth Uhealth; 2020 Oct; 8(10):e20480. PubMed ID: 33064100
[TBL] [Abstract][Full Text] [Related]
17. Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Leong C; Czaykowski P; Geirnaert M; Katz A; Dragan R; Yogendran M; Raymond C
Can J Public Health; 2021 Jun; 112(3):530-540. PubMed ID: 33471346
[TBL] [Abstract][Full Text] [Related]
18. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
19. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
[TBL] [Abstract][Full Text] [Related]
20. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
